"bms" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonOur impact - Bristol Myers Squibb
Our impact Bristol Myers Squibb
BMS secures subcutaneous Opdivo approval - FirstWord Pharma
BMS secures subcutaneous Opdivo approval FirstWord Pharma
With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant...
With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant Sotyktu FiercePharma
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects - Fierce Biotech
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects Fierce Biotech
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century BioSpace
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo - Reuters
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo Reuters
Families flock to BMS for yearly ice rink activities - WJHL-TV News Channel 11
Families flock to BMS for yearly ice rink activities WJHL-TV News Channel 11
Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model - Fierce healthcare
Bristol Myers Squibb latest drug company to sue HHS over 340B rebate model Fierce healthcare
Positive Phase III trials results with BMS’ Sotyktu - The Pharma Letter
Positive Phase III trials results with BMS’ Sotyktu The Pharma Letter
Working at BMS - Bristol Myers Squibb
Working at BMS Bristol Myers Squibb
BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Centu...
BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics Fierce Biotech
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls o...
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls on FiercePharma
Psoriasis around the world - Bristol Myers Squibb
Psoriasis around the world Bristol Myers Squibb
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space - FiercePharma
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space FiercePharma
Our technologies - Bristol Myers Squibb
Our technologies Bristol Myers Squibb
Michael R. McMullen - Bristol Myers Squibb
Michael R. McMullen Bristol Myers Squibb
Advancing Lymphoma Treatment with Protein Degradation - Bristol Myers Squibb
Advancing Lymphoma Treatment with Protein Degradation Bristol Myers Squibb
Post study drug access to BMS investigational medicinal products and approved products - Bristol ...
Post study drug access to BMS investigational medicinal products and approved products Bristol Myers Squibb
Breaking barriers: SOGIIS data collection for improved health equity in clinical trials - Bristol...
Breaking barriers: SOGIIS data collection for improved health equity in clinical trials Bristol Myers Squibb
Our science - Bristol Myers Squibb
Our science Bristol Myers Squibb
Professional Service Automation Software for IT Professionals | Kaseya BMS - Kaseya
Professional Service Automation Software for IT Professionals | Kaseya BMS Kaseya
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal - BioSpace
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal BioSpace
Our research in neuroscience - Bristol Myers Squibb
Our research in neuroscience Bristol Myers Squibb
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma - OncLive
BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma OncLive
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC - OncLive
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC OncLive
Highlights from our 2024 Climate Change Report - Bristol Myers Squibb
Highlights from our 2024 Climate Change Report Bristol Myers Squibb
Early innovation at BMS - Bristol Myers Squibb
Early innovation at BMS Bristol Myers Squibb
Science Firsthand: The pathway to drug discovery - Bristol Myers Squibb
Science Firsthand: The pathway to drug discovery Bristol Myers Squibb
BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 - Fierce Biotech
BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 Fierce Biotech
Leveraging AI to enhance workplace innovation & efficiency - Bristol Myers Squibb
Leveraging AI to enhance workplace innovation & efficiency Bristol Myers Squibb
Science Firsthand: Translating the promise of cell therapy - Bristol Myers Squibb
Science Firsthand: Translating the promise of cell therapy Bristol Myers Squibb
BMS stakes new ground for Sotyktu with Phase III wins in psoriatic arthritis - FirstWord Pharma
BMS stakes new ground for Sotyktu with Phase III wins in psoriatic arthritis FirstWord Pharma
Survivorship Today: Cancer survivor stories - Bristol Myers Squibb
Survivorship Today: Cancer survivor stories Bristol Myers Squibb
MEDIAPRO BMS Wins Cine&Tele Magazine Award for Best Technical Services - Sports Video Group
MEDIAPRO BMS Wins Cine&Tele Magazine Award for Best Technical Services Sports Video Group
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments BioSpace
Our commitment towards transforming multiple myeloma treatment - Bristol Myers Squibb
Our commitment towards transforming multiple myeloma treatment Bristol Myers Squibb
A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management - Bris...
A new era in Alzheimer's R&D: Dual approach to disease modification and symptom management Bristol Myers Squibb
AI-driven protein degradation research reshaping drug discovery - Bristol Myers Squibb
AI-driven protein degradation research reshaping drug discovery Bristol Myers Squibb
ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Dir...
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluatin...
BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years - BioSpace
BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years BioSpace
Celebrating four years of patient engagement through PEER program - Bristol Myers Squibb
Celebrating four years of patient engagement through PEER program Bristol Myers Squibb
ASPIRE: Our commitment to address health inequities in low- and middle-income countries - Bristol...
ASPIRE: Our commitment to address health inequities in low- and middle-income countries Bristol Myers Squibb
AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for M...
Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) - Bristol Mye...
Commitment to safety and patients: Risk evaluation and mitigation strategies (REMS) Bristol Myers Squibb
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipelin...
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline Fierce Biotech
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $...
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research Bristol Myers Squibb - News
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Th...
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma Bristol Myers Squibb - News
Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking ...
Q&A with Robert Plenge: What is Bristol Myers Squibb’s research strategy and where are we taking it? Bristol Myers Squibb
Continuing Innovations on TYK2 Inhibition - Bristol Myers Squibb
Continuing Innovations on TYK2 Inhibition Bristol Myers Squibb
Reigniting Innovation in Neuropsychiatry - Bristol Myers Squibb
Reigniting Innovation in Neuropsychiatry Bristol Myers Squibb
How BMS employees champion STEM education & diversity - Bristol Myers Squibb
How BMS employees champion STEM education & diversity Bristol Myers Squibb
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent - BioSpace
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent BioSpace
Developing tools to break the rules: Fostering innovation in cell therapy manufacturing - Bristol...
Developing tools to break the rules: Fostering innovation in cell therapy manufacturing Bristol Myers Squibb
BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study - BioSpace
BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study BioSpace
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink - FiercePharma
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink FiercePharma
Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends - BioSpace
Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends BioSpace
BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing -...
BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing FiercePharma
Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research - Bristol Myers Squibb
Celebrating 11 Years of C2C4C to Raise Funds for Cancer Research Bristol Myers Squibb
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administrat...
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma Bristol Myers Squibb - News
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific - Fierce Biotech
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific Fierce Biotech
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia - BioSpace
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia BioSpace
Former BMS Professor and GeniPhys Founder Sees Continued Success in Development of Wound Manageme...
Former BMS Professor and GeniPhys Founder Sees Continued Success in Development of Wound Management Product Purdue University
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer fiel...
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field FiercePharma
Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace
Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline BioSpace
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapse...
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Bristol Myers Squibb - News
BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody - BioSpace
BMS Backs Out of $1.5B Deal, Returns Rights to Agenus for Bispecific Antibody BioSpace
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' - ...
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' FiercePharma
Bringing the science of cell therapy into autoimmune diseases - Bristol Myers Squibb
Bringing the science of cell therapy into autoimmune diseases Bristol Myers Squibb
Chris Boerner, PhD - Bristol Myers Squibb
Chris Boerner, PhD Bristol Myers Squibb
BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs - BioSpace
BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs BioSpace
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s - PharmaVoice
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s PharmaVoice
Spreading eosinophilic esophagitis awareness and wellness in patients - Bristol Myers Squibb
Spreading eosinophilic esophagitis awareness and wellness in patients Bristol Myers Squibb
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on - Fierce...
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on FiercePharma
Amplifying patient voices to enhance HCM care - Bristol Myers Squibb
Amplifying patient voices to enhance HCM care Bristol Myers Squibb
5 Schizophrenia Candidates Chasing BMS’ KarXT - BioSpace
Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition - BioSpace
Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition BioSpace
Exploring New Treatment Options for Pulmonary Fibrosis - Bristol Myers Squibb
Exploring New Treatment Options for Pulmonary Fibrosis Bristol Myers Squibb
Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace
Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment BioSpace
BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC - BioSpace
BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC BioSpace
Improving health literacy through Universal Patient Language program - Bristol Myers Squibb
Improving health literacy through Universal Patient Language program Bristol Myers Squibb
FDA Approves First Novel Schizophrenia Drug in 35 Years - BioSpace
FDA Approves First Novel Schizophrenia Drug in 35 Years BioSpace
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval - FiercePharma
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval FiercePharma
Research to Help Replace Medication Infusions with Quick Injections to Launch on SpaceX CRS-27 - ...
Research to Help Replace Medication Infusions with Quick Injections to Launch on SpaceX CRS-27 ISS National Lab
AstraZeneca, BMS, J&J Renew Legal Challenge to IRA Before Appeals Court - BioSpace
AstraZeneca, BMS, J&J Renew Legal Challenge to IRA Before Appeals Court BioSpace
Building a better future: Bristol Myers Squibb 2023 ESG report - Bristol Myers Squibb
Building a better future: Bristol Myers Squibb 2023 ESG report Bristol Myers Squibb
Harnessing the Potential of Anti-Cancer Modalities - Bristol Myers Squibb
Harnessing the Potential of Anti-Cancer Modalities Bristol Myers Squibb
BMS Will Lay Off 79 in Lawrenceville, NJ, Bringing City’s Employee Cuts to 1,134 - BioSpace
BMS Will Lay Off 79 in Lawrenceville, NJ, Bringing City’s Employee Cuts to 1,134 BioSpace
Advancing oncology care: The potential of subcutaneous immunotherapy - Bristol Myers Squibb
Advancing oncology care: The potential of subcutaneous immunotherapy Bristol Myers Squibb
Biogen boosts C-suite with BMS vet—Chutes & Ladders - Fierce Biotech
Biogen boosts C-suite with BMS vet—Chutes & Ladders Fierce Biotech
Driving cutting-edge research for treating blood disorders - Bristol Myers Squibb
Driving cutting-edge research for treating blood disorders Bristol Myers Squibb
Equipping providers in underserved communities to improve lung cancer care - Bristol Myers Squibb
Equipping providers in underserved communities to improve lung cancer care Bristol Myers Squibb
Bridging the cancer care gap in LMICs with innovation and collaboration - Bristol Myers Squibb
Bridging the cancer care gap in LMICs with innovation and collaboration Bristol Myers Squibb
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet - Fierce Biotech
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet Fierce Biotech
BMS analytics head Conrad leaving as ProLink defections also continue - Re-Insurance.com
BMS analytics head Conrad leaving as ProLink defections also continue Re-Insurance.com
Bristol Myers partner Zai Lab plots KarXT filing in China after trial win - FiercePharma
Bristol Myers partner Zai Lab plots KarXT filing in China after trial win FiercePharma
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been...
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been FiercePharma
BMS scores another win against Sandoz and Teva over apixaban in Den Haag - JUVE Patent
BMS scores another win against Sandoz and Teva over apixaban in Den Haag JUVE Patent